Remond J A Fijneman

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression
    Anke H Sillars-Hardebol
    VU University Medical Center, Department of Pathology, De Boelelaan 1117, Amsterdam, The Netherlands
    Gut 61:1568-75. 2012
  2. ncbi Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer
    Remond J A Fijneman
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 18:2613-24. 2012
  3. ncbi Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3
    Remond J A Fijneman
    Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:3458-64. 2004
  4. ncbi Genetic predisposition to sporadic cancer: how to handle major effects of minor genes?
    Remond J A Fijneman
    Depatment of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 27:281-92. 2005
  5. ncbi Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer
    Remond J A Fijneman
    Department of Medical Oncology, VU University Medical Center, CCA 2 60, P O Box 7057, 1007MB Amsterdam, The Netherlands
    Cancer Lett 258:223-9. 2007
  6. ncbi CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol (Dordr) 35:293-300. 2012
  7. ncbi Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Tumour Biol 31:89-96. 2010
  8. ncbi Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression
    Meike de Wit
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, Amsterdam, The Netherlands
    Gut 61:855-64. 2012
  9. ncbi Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression
    Jakob Albrethsen
    OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center VUmc Cancer Center Amsterdam, The Netherlands
    Mol Cell Proteomics 9:988-1005. 2010
  10. ncbi Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways
    Remond J A Fijneman
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 31:345-56. 2009

Collaborators

Detail Information

Publications20

  1. ncbi TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression
    Anke H Sillars-Hardebol
    VU University Medical Center, Department of Pathology, De Boelelaan 1117, Amsterdam, The Netherlands
    Gut 61:1568-75. 2012
    ..The aim of this study was to identify genes located on the 20q amplicon that promote progression of colorectal adenoma to carcinoma...
  2. ncbi Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer
    Remond J A Fijneman
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 18:2613-24. 2012
    ..Early detection of colorectal cancer (CRC) and its precursor lesions is an effective approach to reduce CRC mortality rates. This study aimed to identify novel protein biomarkers for the early diagnosis of CRC...
  3. ncbi Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3
    Remond J A Fijneman
    Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:3458-64. 2004
    ..These studies provide a novel approach to investigate the genetics of microenvironmental influence on predisposition to tumorigenesis, thereby contributing to development of new strategies that aim to prevent or treat cancer...
  4. ncbi Genetic predisposition to sporadic cancer: how to handle major effects of minor genes?
    Remond J A Fijneman
    Depatment of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 27:281-92. 2005
    ..New strategies need to be developed to evaluate cancer risk associated with biological modules that are influenced by TSG-networks...
  5. ncbi Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer
    Remond J A Fijneman
    Department of Medical Oncology, VU University Medical Center, CCA 2 60, P O Box 7057, 1007MB Amsterdam, The Netherlands
    Cancer Lett 258:223-9. 2007
    ....
  6. ncbi CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol (Dordr) 35:293-300. 2012
    ..This study aimed to investigate whether CSE1L, DIDO1 and RBM39 may drive 20q amplification...
  7. ncbi Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
    Anke H Sillars-Hardebol
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Tumour Biol 31:89-96. 2010
    ....
  8. ncbi Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression
    Meike de Wit
    Department of Pathology Tumor Profiling Unit, VU University Medical Center, Amsterdam, The Netherlands
    Gut 61:855-64. 2012
    ..The authors aimed to identify cell surface protein biomarkers with extracellular domains that could be targeted for molecular imaging and discriminate low-risk adenomas and normal colon from high-risk adenomas and CRC...
  9. ncbi Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression
    Jakob Albrethsen
    OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center VUmc Cancer Center Amsterdam, The Netherlands
    Mol Cell Proteomics 9:988-1005. 2010
    ..Together, the results show that subnuclear proteomics of tumor tissue is feasible and a promising avenue for exploring oncogenesis...
  10. ncbi Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways
    Remond J A Fijneman
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 31:345-56. 2009
    ..However, it is unclear how Pla2g2a exerts its tumor-suppressive effects and whether its mode of action depends on Apc-germline mutations...
  11. ncbi Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism
    Beatriz Carvalho
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol (Dordr) 35:53-63. 2012
    ..It is estimated that only about 5% of adenomas do progress to a carcinoma...
  12. ncbi The adenoma hunt in colorectal cancer screening: defining the target
    Anke H Sillars-Hardebol
    Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands
    J Pathol 226:1-6. 2012
    ..Screening tests based on genomic changes that affect relevant biological and metabolic processes hold most promise in this respect...
  13. ncbi Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract
    Remond J A Fijneman
    Department of Pathology, VU University Medical Center, Amsterdam, Netherlands
    Cancer Sci 103:593-9. 2012
    ....
  14. ncbi Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum
    Astrid E Greijer
    Department of Pathology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Virchows Arch 452:535-44. 2008
    ....
  15. ncbi Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers
    Connie R Jimenez
    OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Proteomics 73:1873-95. 2010
    ....
  16. ncbi Molecular tests for colorectal cancer screening
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Colorectal Cancer 10:8-23. 2011
    ..Evaluation in large well-controlled randomized trials is the next step needed to take molecular markers for CRC screening to the next level and warrant implementation in a screening setting...
  17. ncbi Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications
    Meike de Wit
    Department of Medical Oncology, OncoProteomics Laboratory, VU University Medical Center, Amsterdam, The Netherlands
    Clin Biochem 46:466-79. 2013
    ..Antibodies are still required, though, both to perform high-throughput validation as well as to develop cost-effective tests for routine use in a clinical setting...
  18. ncbi The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine
    Remond J A Fijneman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Front Biosci 13:4144-74. 2008
    ..In this review we aim to summarize current knowledge about the various links of sPLA2-IIA to cancer of the gastro-intestinal tract, and propose several models to illustrate its putative biological effects on tumor development...
  19. ncbi Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice
    Edwin Kanters
    Department of Molecular Cell Biology and Immunology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Invest 112:1176-85. 2003
    ..Our data show that inhibition of the NF-kappaB pathway in macrophages leads to more severe atherosclerosis in mice, possibly by affecting the pro- and anti-inflammatory balance that controls the development of atherosclerosis...
  20. ncbi Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (lymphocyte infiltration) loci
    Neelima Kakarlapudi
    Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 57:217-25. 2008
    ..Such prediction of probability of tumor infiltration in individual cancer patients could help considerably to assess their prognosis and to decide about the application and the type of immunotherapy...